Sai Parenteral’s IPO: A Weak Start on Day 1
The initial public offering (IPO) of Sai Parenteral’s, a diversified pharmaceutical formulations company, has got off to a slow start, with the issue being subscribed only 0.05 times on the first day of bidding. The company is looking to raise ₹285 crore through the IPO, which will be used for growth initiatives, including manufacturing upgrades and debt repayment.
As per the data available on the stock exchanges, the issue received bids for 3.35 lakh shares against the total issue size of 72.99 lakh shares. The retail portion of the IPO was subscribed 0.03 times, while the non-institutional investor (NII) portion was subscribed 0.15 times. The qualified institutional buyer (QIB) portion has not yet opened for bidding.
IPO Details: What You Need to Know
The Sai Parenteral’s IPO is a combination of a fresh issue of 0.73 crore shares aggregating to ₹285 crore and an offer for sale of 0.32 crore shares aggregating to ₹123.79 crore. The price band for the IPO has been fixed at ₹372-₹392 per share. Investors can apply for the IPO in lots of 38 shares, with a minimum investment of ₹14,896 required to apply for one lot.
The company plans to utilize the proceeds from the fresh issue to fund its growth initiatives, including capacity expansion and upgradation of manufacturing facilities, establishment of a new R&D centre, and debt repayment. The remaining portion will be used for general corporate purposes.
Grey Market Premium: What It Indicates
The grey market premium (GMP) of Sai Parenteral’s is currently showing nil, indicating that the stock might list at the same price as the IPO price. This could be a concern for investors who were expecting a decent listing gain. However, it’s essential to note that the GMP is not always a reliable indicator of the stock’s performance on the listing day.
To get a better understanding of the pharmaceutical sector in India and its trends, it’s crucial to analyze the sector’s performance and the company’s position within it. The pharmaceutical sector is a significant contributor to the Indian economy, and companies like Sai Parenteral’s play a vital role in it.
About Sai Parenterals: A Diversified Pharmaceutical Formulations Player
Sai Parenteral’s is a diversified pharmaceutical formulations player with capabilities in research, development, and manufacturing. The company operates in the branded generic formulations segment and also provides contract development and manufacturing organisation (CDMO) products and services for domestic and international markets.
The company’s portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. It offers a wide range of dosage forms, including injectables, tablets, capsules, liquid orals, and ointments.
In the injectables segment, the company has capabilities in sterile manufacturing for critical care and penicillin-based therapies, offering delivery systems such as dry powder injections, pre-filled syringes, ampoules, and vials.
Investor Takeaway: What to Expect from the IPO
The weak response to the Sai Parenteral’s IPO on Day 1 may be a concern for investors. However, it’s essential to note that the IPO market is highly volatile, and investor sentiment can change quickly. The company’s fundamentals, growth prospects, and valuation multiples will ultimately determine the IPO’s success.
Investors who are considering applying for the IPO should carefully evaluate the company’s financials, management team, and industry trends before making an informed decision. It’s also crucial to keep an eye on the stock market news and updates to stay ahead of the curve.
For more information on the Indian stock market trends and pharmaceutical sector trends, you can visit our website and stay updated with the latest news and analysis.